iPharma is an accredited partner of Skolkovo Technopark and a member of the Chemrar center of Advanced Technology. We specialize in the conduct of clinical trials in Russia, EAEU countries, Serbia, China and Australia.

iPharma provides a full cycle of clinical development of drugs from early phases to registration, as well as

medical examination and post-marketing programs based on the optimal strategy for bringing the drug

to market. We have conducted more than 310 clinical studies in various therapeutic areas: oncology,

virology, endocrinology, pulmonology, neurology, psychiatry, transplantology and others.

Among the leaders in the AOKI 2022 ranking

IPHARMA organizes clinical trials of Russian and foreign drugs in order to register them in Russia, EAEU countries, Serbia, China and Australia.
Our experienced team guarantees fast and high-quality conduct of clinical trials in various therapeutic areas, as well as highly qualified medical expertise, monitoring and audit of data in accordance with international and Russian standards.

IPHARMA collaborates with leading pharmaceutical and biotechnological companies. The Chemrar Centre of Advanced Technology scientific research platform greatly expands our clients’ opportunities for chemical synthesis, development and production of finished dosage forms, conduct of pre-clinical and bioanalytical studies, as well as providing various financial instruments.

IPHARMA provides free consultations regarding the possibility, timeframes and costs of the conduct of clinical trials for innovative and generic medicines. If necessary, we can provide recommendations on the optimization of study design by consulting with our medical advisors and leading specialists in the corresponding therapeutic areas.

Our mission

iPharma is a reliable partner and the perfect platform for clinical development of new medicines and IT solutions

Our values

Our company aims to contribute to the growth of the healthcare sector and we prioritize our patients’ interests.

Patient safety and the well-being of society

Clients’ and partners’ trust

Professionalism and stable growth

Objective and accurate data

Development of medical science and the health of future generations

"We work so that all effective and safe medical technologies and drugs can be available to Russian residents"

Natalia Rabinovich, CEO of iPharma

Our history

2012

iPharma was created in 2012 by the Chemrar Centre of Advanced Technology in order to implement full-cycle clinical development of innovative drugs. The company was led by a team of specialists with extensive experience in conducting international and local clinical trials.

2013

In 2013, iPharma acted as a co-executor on 10 government contracts in the field of transfer of foreign developments, organization and conduct of clinical trials of innovative medicines. 7 permits from the Ministry of Health of the Russian Federation were received to conduct clinical studies on diabetes mellitus, schizophrenia, hepatitis C, melanoma, lung cancer, ovarian cancer and the prevention of thromboembolic complications in orthopedics. According to the Information and Analytical Bulletin of the Association of Clinical Trials Organizations (ACTO), based on the results of the year, iPharma is the leader in the number of studies of Russian innovative drugs.

2014

In 2014, we initiated an internship program for young specialists in clinical trials and participated in conferences which discussed relevant topics in clinical and pre-clinical trials of medical devices and drugs. We obtained 9 Ministry of Health permits for the conduct of clinical trials on HIV, Hepatitis C, liver transplant, non-Hodgkins’s lymphoma, kidney cancer and bronchial asthma. According to the info-analytical ACTO bulletin of that year, iPharma maintains leading positions in the number of Russian innovative drug trials conducted.

2015

In 2015 we opened a new office in Skolkovo Technopark and participated in international exhibitions such as 75th Scientific Sessions ADA, Boston, MA, 51st Annual Meeting DIA, Washington, DC. We received 8 Ministry of Health permits for clinical studies on flu, rheumatoid arthritis, Hepatitis B and C, Meniere's disease, ovarian cancer and bronchial asthma. According to the ACTO Information and Analytical Bulletin based on the results of the year, iPharma maintains its leading position in the number of studies of Russian innovative drugs.

2016

In 2016 we initiated our pharmacovigilance system for researched drugs and conducted seminars within the Skolkovo Open University educational program Pharma’s cool. Agreement on scientific cooperation with the First Moscow State Medical University named after. THEM. Sechenov. Performances at international exhibitions 28th Annual EuroMeeting DIA, Hamburg, Germany and 52nd Annual Meeting DIA, Philadelphia, PA. Participation in international cooperation programs with the Czech Republic and Cuba. The original drugs Gozogliptin and Normacor, clinical trials of which were organized and conducted by IPHARMA, received registration certificates. 8 permits from the Ministry of Health of the Russian Federation were received to conduct clinical studies on diabetes mellitus, cough, hepatitis C, breast cancer, lung cancer, Meniere's disease, metabolic syndrome and ARVI. We obtained 15 permits from the Ministry of Health of the Russian Federation were received. According to the ACTO Information and Analytical Bulletin, based on the results of 2017, IPHARMA took first place among local CROs.

2017

In 2017 we participated in international and local conferences and programs GeneratonS, DIA 2017 Annual Meeting, 6th International Forum “Clinical Research in Russia”, III All-Russian Endocrinological Congress, etc. Conducting seminars within the educational programs of the Open University Skolkovo Pharma's cool, the biomedical research cluster of the Foundation " Skolkovo" "Development of innovative drugs", Department of Industrial Pharmacy, Faculty of Pharmacy, First Moscow State Medical University named after. THEM. Sechenov. Organization and holding of the Social Pharmaceutical Forum “The Patient as a Partner: Drug Development, Clinical Research and Innovative Treatment Methods” and the first in-person meeting of the Clinical Trials Quality Assurance Forum.

2018

In 2018 we obtained 7 permits from the Ministry of Health of the Russian Federation. According to the ACTO Information and Analytical Bulletin, based on the results of 2018, IPHARMA took first place among local CROs. Launch of two new services: registration of medicines and medical devices, data processing and biostatistics. Participation in international and local conferences of DIA, Adam Smith Institute, Skolkovo Innovation Foundation. In 2018, IPHARMA launched www.ClinLine.ru - the first platform for interaction between patients, researchers and clinical trial organizers in Russia. The platform was developed within the framework of the NeuroNet roadmap of the National Technology Initiative with the support of the Federal State Budgetary Institution “Fund for Assistance to the Development of Small Innovative Enterprises in the Scientific and Technical Sphere.”

2019

In 2019 we obtained 11 permits from the Ministry of Health of the Russian Federation. We participated in international and local DIA conferences, Adam Smith Institute, Skolkovo Innovation Foundation. Representation of the Russian clinical research market in China (PuE Business Mission in Pharma) and Japan (KOBE Biomedical Innovation Cluster). The iDossier program has been developed to prepare a dossier in the EOTD format in accordance with the requirements of the EAEU. In 2019, the ProDrug mobile application was launched to search for medications, information about their effectiveness, contraindications and analogues. The application is available in the Google Play store. Students were trained as part of the Pharma’s cool educational programs at Skolkovo University and StudStock at MIPT.

2020

In 2020, 16 permits from the Ministry of Health of the Russian Federation were received. At the end of 2020, IPHARMA took 1st place in two CRO ratings in terms of the number of local clinical trials and bioequivalence studies conducted according to the information and analytical bulletin of the Association of Clinical Research Organizations. 10 clinical trials of drug candidates for the treatment and prevention of COVID-19 were launched, including the Gam-COVID-Vac vaccine in the Republic of Belarus, with the participation of more than 1,000 patients. 3 original medicines have been registered, including a vaccine, in Belarus. As well as 14 medical products: PCR tests and immunochromatographic rapid tests for the detection of antibodies and antigen to SARS-CoV-2. A new service has been introduced - user testing of the package insert. Participation in international and local conferences Pharma Week in the EAEU 2020, VI St. Petersburg International Oncology Forum White Nights and Clinical Trials in Russia Adam Smith Conferences. The 5th year students of the Department of Innovative Pharmaceuticals, Medical Equipment and Biotechnology of the Moscow Institute of Physics and Technology were trained in “Biostatistics in Clinical Research”.